



**CERTIFICATE OF ANALYSIS**  
**EQAPOL Spiked-Plasma Panel**  
**Created for PATH Grand Challenges Program**

**Genetic Subtype B Spiked Plasma Panel**

Subtype: B  
GenBank Accession Number: JX140657  
Sample Concentration:

<b>Sample Name</b>	<b>VL (cp/mL) ± SD (Roche Version 2.0)</b>
<b>DEGCBH.01</b>	72,583 ± 17,560
<b>DEGCBM.01</b>	9,785 ± 1,056
<b>DEGCBL.01</b>	1,045 ± 166
<b>DEGCBVL.01</b>	230 ± 65
<b>DEGCBN.01</b>	0

Co-receptor Usage (NP-2 Cell Assay): CCR5

**Source Specimen Information**

Source Contributor: Mike Busch, Blood System Research Institute  
(BSRI, San Francisco, CA); Susan Stramer,  
American Red Cross

Source Material: Plasma

Fiebig Stage of Source Plasma: I/II (Nat Yield)

Country of Origin for Source Specimen: USA

Age: Unknown

Sex: Unknown

Race: Unknown

Risk: Unknown

Year of Donation for Source Specimen: 2009

EQAPOL  
Duke University Medical Center  
2 Genome Court  
Durham, NC, 27710  
EQAPOL@duke.edu



 **Duke Human Vaccine Institute**

### **Genetic Subtype C Spiked Plasma Panel**

Subtype: C  
GenBank Accession Number: JX140667  
Sample Concentration:

<b>Sample Name</b>	<b>VL (cp/mL) <math>\pm</math> SD (Roche Version 2.0)</b>
<b>DEGCCH.01</b>	210,667 $\pm$ 24,155
<b>DEGCCM.01</b>	20,965 $\pm$ 10,498
<b>DEGCCL.01</b>	3,172 $\pm$ 420
<b>DEGCCVL.01</b>	703 $\pm$ 128
<b>DEGCCN.01</b>	0

Co-receptor Usage (NP-2 Cell Assay): CCR5

### **Source Specimen Information**

Source Contributor: Mike Busch, Blood System Research Institute (BSRI, San Francisco, CA); Marion Vermeulen, South Africa National Blood Service

Source Material: Plasma

Fiebig Stage of Source Plasma: Indeterminate (Nat Yield)

Country of Origin for Source Specimen: South Africa

Age: 16

Sex: F

Race: Black

Risk: Unknown

Year of Donation for Source Specimen: 2008

EQAPOL  
Duke University Medical Center  
2 Genome Court  
Durham, NC, 27710  
EQAPOL@duke.edu



 **Duke Human Vaccine Institute**

### **Genetic Subtype D Spiked Plasma Panel**

Subtype: D  
GenBank Accession Number: JX140670  
Sample Concentration:

<b>Sample Name</b>	<b>VL (cp/mL) ± SD (Roche Version 2.0)</b>
<b>DEGCDH.01</b>	86,667 ± 20,462
<b>DEGCDM.01</b>	12,068 ± 3,104
<b>DEGCDL.01</b>	1,333 ± 198
<b>DEGCDVL.01</b>	280 ± 59
<b>DEGCDN.01</b>	0

Co-receptor Usage (NP-2 Cell Assay): CCR5/CXCR4

### **Source Specimen Information**

Source Contributor Indira Hewlett, Laboratory of  
Molecular Virology, CBER/FDA  
Source Material Viral Culture Supernatant  
Fiebig Stage of Source Plasma: VI  
Country of Origin for Source Specimen: Cameroon  
Year of Donation for Source Specimen: 2010  
Age: Unknown  
Sex: Unknown  
Race: Unknown  
Risk: Unknown

EQAPOL  
Duke University Medical Center  
2 Genome Court  
Durham, NC, 27710  
EQAPOL@duke.edu



 **Duke** Human Vaccine Institute

### Notes

All oral presentations or written publications concerning research utilizing EQAPOL samples should include the following acknowledgement: "This work has been supported in whole or part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Contract Number NOI-AI-85341." The provider(s) of source material should also be acknowledged in oral presentation and written publications.

A handwritten signature in black ink, appearing to be "C. F. H.", is written over a horizontal line.

Quality Assurance Signature

30/JAN/13

Date